CRKL and chronic myelogenous leukemia, BCR-ABL1 positive: We showed that imatinib (20 μM) decreased the total phosphotyrosine level and abrogated most of the phospho-CRK-like protein (CRKL) in CML-iPSCs Ph+ (Fig 3D).